Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy | Hematology | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.236.187.155. Please contact the publisher to request reinstatement.
1.
Lischke  T, Heesch  K, Schumacher  V,  et al.  CD38 controls the innate immune response against Listeria monocytogenes.  Infect Immun. 2013;81(11):4091-4099. doi:10.1128/IAI.00340-13PubMedGoogle ScholarCrossref
2.
Amici  SA, Young  NA, Narvaez-Miranda  J,  et al.  CD38 Is robustly induced in human macrophages and monocytes in inflammatory conditions.  Front Immunol. 2018;9:1593. doi:10.3389/fimmu.2018.01593PubMedGoogle ScholarCrossref
3.
Dimopoulos  MA, Oriol  A, Nahi  H,  et al; POLLUX Investigators.  Daratumumab, lenalidomide, and dexamethasone for multiple myeloma.  N Engl J Med. 2016;375(14):1319-1331. doi:10.1056/NEJMoa1607751PubMedGoogle ScholarCrossref
4.
Altman  DG.  Practical Statistics for Medical Research. London: Chapman & Hall; 1991.
5.
Johnsen  BO, Lingaas  E, Torfoss  D, Strøm  EH, Nordøy  I.  A large outbreak of Listeria monocytogenes infection with short incubation period in a tertiary care hospital.  J Infect. 2010;61(6):465-470. doi:10.1016/j.jinf.2010.08.007PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Research Letter
    November 27, 2019

    Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy

    Author Affiliations
    • 1Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
    • 2Department of Infection Prevention and Control, University Health Network, Toronto, Ontario, Canada
    • 3Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    • 4Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    JAMA Oncol. 2020;6(2):293-294. doi:10.1001/jamaoncol.2019.5098

    Daratumumab is a human immunoglobulin G1κ monoclonal antibody directed against cluster of differentiation (CD) 38 that received US Food and Drug Administration approval in 2017 as multiple myeloma therapy. While CD38 is highly expressed by myeloma cells, it is also expressed by activated macrophages and appears to play an important role in Listeria defense, inhibiting the infection of the macrophage cytoplasm by phagocytosed bacilli and preventing macrophage-based dissemination.1 In mice, CD38 inactivation causes a marked susceptibility to Listeria monocytogenes. As CD38 is also induced on human macrophages, identical mechanisms may underlie human Listeria protection.2

    Clinical trials have characterized daratumumab’s safety profile and demonstrated only a mild infection risk.3 However, because preclinical models of CD38 inactivation are associated with increased L monocytogenes susceptibility, we assessed the risk of listeriosis in patients receiving anti-CD38 daratumumab therapy.

    ×